Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Givinostat HCl
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Recipient : PANTHERx Rare Pharmacy
Deal Size : Undisclosed
Deal Type : Partnership
PANTHERx®Rare Partnering with ITF Therapeutics LLC for U.S. Distribution of DUVYZAT™
Details : PANTHERx partners with ITF for the U.S. distribution of Duvyzat (givinostat), the approved product to treat patients with all genetic variants of Duchenne muscular dystrophy aged six years and older.
Product Name : Duvyzat
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 25, 2024
Lead Product(s) : Givinostat HCl
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Recipient : PANTHERx Rare Pharmacy
Deal Size : Undisclosed
Deal Type : Partnership
Reset All
